Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Surgical resection with adjuvant chemotherapy is the only treatment that can provide long term survival in localized pancreatic ductal adenocarcinoma (LPDAC). Notwithstanding, recurrence occurs in the vast majority of patients and a better stratification of preoperative therapies is required. This study aimed to investigate preoperative immunological and nutritional factors to predict relapse-free survival (RFS) in patients with LPDAC.
Methods: Analyses were derived from all consecutive LPDAC patients treated with surgical resection at Besancon University Hospital, France, between January 2006 and December 2014 (n=146). Biological and nutritional parameters were recorded before and after surgery. The association of 24 baseline parameters with RFS was evaluated using univariate and multivariate Cox analyses. Based on the final model, a prognostic score was developed.
Results: Lymphocyte count and body composition were available for 94 patients. In multivariate analysis, preoperative lymphopenia and sarcopenia (or a low muscle mass) were identified as independent prognostic factors for RFS. The score determined three groups with a median RFS of 5.6 months (95% confidence interval [CI] = 4.3 to 9.6 months) for high-risk group, corresponding to patients with lymphopenia; 11.5 months (95%CI = 9.8 to 13.9 months), and 21.2 months (95%CI = 9.9 to 55.3 months), for intermediate-(patient with sarcopenia without lymphopenia), and low-risk groups (no risk factor), respectively (p <0.001). Preoperative sarcopenia predicts the occurrence of postoperative lymphopenia in patients with a preoperative lymphocyte count above 1,000/mm (p = 0.0029).
Conclusions: Preoperative lymphopenia and sarcopenia are pejorative prognostic factors in LPDAC and should be considered in the preoperative evaluation to stratify death risk in patients with LPDAC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190386 | PMC |
| http://dx.doi.org/10.3389/fonc.2021.683289 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prehabilitation of Patients With Oesophageal Malignancy Undergoing Peri-Operative Treatment (Pre-EMPT): Outcomes From a Prospective Controlled Trial.
J Surg Oncol
June 2025
Department of Upper GI and General Surgery, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Background: The Pre-EMPT study aimed to determine if structured exercise could reduce length of stay, post-operative complications and improve fitness and health-related quality of life (HQRL) in patients undergoing neoadjuvant chemotherapy (NAC) and oesophagectomy.
Methods: A prospective non-randomised trial compared a standard care pathway (control) to a structured prehabilitation exercise programme (intervention) commenced before NAC and surgery for oesophageal adenocarcinoma. Length of hospital stay and post-operative complications were recorded.
Unraveling the Impact of Sarcopenia-Induced Lymphopenia on Treatment Response and Prognosis in Patients with Stage III Non-Small Cell Lung Cancer: Insights for Optimizing Chemoradiation and Immune Checkpoint Inhibitor.
Cancer Res Treat
April 2025
Department of Radiation Oncology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Article Synopsis
- Sarcopenia, a condition characterized by loss of muscle mass, negatively impacts the prognosis of patients with stage III non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors (ICIs) after concurrent chemoradiotherapy (CCRT).
- In a study of 151 NSCLC patients, those with sarcopenia before radiotherapy showed poorer lymphocyte recovery and a higher likelihood of severe lymphopenia during treatment, which are both linked to worse overall survival and progression-free survival.
- The findings suggest that sarcopenia and the resulting lymphopenia may hinder the effectiveness of ICIs and contribute to inferior treatment outcomes, highlighting the need for attention to these factors in patient management.
R-ketorolac ameliorates cancer-associated cachexia and prolongs survival of tumour-bearing mice.
J Cachexia Sarcopenia Muscle
April 2024
Institute of Molecular Biosciences, University of Graz, Graz, Austria.
Background: Cancer-associated cachexia (CAC) is a debilitating syndrome associated with poor quality of life and reduced life expectancy of cancer patients. CAC is characterized by unintended body weight reduction due to muscle and adipose tissue loss. A major hallmark of CAC is systemic inflammation.
View Article and Find Full Text PDFLow muscle mass measured at T12 is a prognostic biomarker in unresectable oesophageal cancers receiving chemoradiotherapy.
Radiother Oncol
September 2023
Division of Cancer Sciences, University of Manchester, Manchester M13 9PL, UK; Radiotherapy Related Research, The Christie Foundation Trust, Manchester M20 4BX, UK.
Background And Purpose: Low muscle mass is an imaging biomarker of patient frailty that has been associated with increased toxicity and decreased survival in a number of cancers. Patients with unresectable oesophageal cancer receive chemoradiotherapy as standard of care. Muscle mass is not yet an established prognostic marker in this population.
View Article and Find Full Text PDFAdditive Value of Preoperative Sarcopenia and Lymphopenia for Prognosis Prediction in Localized Pancreatic Ductal Adenocarcinoma.
Front Oncol
May 2021
Department of Medical Oncology, University Hospital of Besançon, Besançon, France.
Article Synopsis
- Surgical resection and chemotherapy are the main treatments for localized pancreatic ductal adenocarcinoma (LPDAC), but most patients experience recurrence, highlighting the need for improved preoperative therapy assessments.
- A study at Besancon University Hospital analyzed factors from 146 LPDAC patients to predict relapse-free survival (RFS), focusing on immunological and nutritional elements.
- It found that preoperative lymphopenia (low lymphocyte count) and sarcopenia (low muscle mass) significantly impact RFS, allowing for the classification of patients into three risk groups with varied survival outcomes.